Very Early-Onset Inflammatory Bowel Disease: A Challenging Field for Pediatric Gastroenterologists
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
With the increasing number of children with inflammatory bowel disease (IBD), very early-onset IBD (VEO-IBD), defined as IBD that is diagnosed or that develops before 6 years of age, has become a field of innovation among pediatric gastroenterologists. Advances in genetic testing have enabled the diagnosis of IBD caused by gene mutations, also known as monogenic or Mendelian disorder-associated IBD (MD-IBD), with approximately 60 causative genes reported to date. The diagnosis of VEO-IBD requires endoscopic and histological evaluations. However, satisfactory small bowel imaging studies may not be feasible in this small population. Both genetic and immunological approaches are necessary for the diagnosis of MD-IBD, which can differ among countries according to the available resources. As a result of the use of targeted gene panels covered by the national health insurance and the nationwide research project investigating inborn errors of immunity, an efficient approach for the diagnosis of MD-IBD has been developed in Japan. Proper management of VEO-IBD by pediatric gastroenterologists constitutes a challenge. Some MD-IBDs can be curable by allogenic hematopoietic stem cell transplantation. With an understanding of the affected gene functions, targeted therapies are being developed. Social and psychological support systems for both children and their families should also be provided to improve their quality of life. Multidisciplinary team care would contribute to early diagnosis, proper therapeutic interventions, and improved quality of life in patients and their families.
Abstract
With the increasing number of children with inflammatory bowel disease (IBD), very early-onset IBD (VEO-IBD), defined as IBD that is diagnosed or that develops before 6 years of age, has become a field of innovation among pediatric gastroenterologists. Advances in genetic testing have enabled the diagnosis of IBD caused by gene mutations, also known as monogenic or Mendelian disorder-associated IBD (MD-IBD), with approximately 60 causative genes reported to date. The diagnosis of VEO-IBD requires endoscopic and histological evaluations. However, satisfactory small bowel imaging studies may not be feasible in this small population. Both genetic and immunological approaches are necessary for the diagnosis of MD-IBD, which can differ among countries according to the available resources. As a result of the use of targeted gene panels covered by the national health insurance and the nationwide research project investigating inborn errors of immunity, an efficient approach for the diagnosis of MD-IBD has been developed in Japan. Proper management of VEO-IBD by pediatric gastroenterologists constitutes a challenge. Some MD-IBDs can be curable by allogenic hematopoietic stem cell transplantation. With an understanding of the affected gene functions, targeted therapies are being developed. Social and psychological support systems for both children and their families should also be provided to improve their quality of life. Multidisciplinary team care would contribute to early diagnosis, proper therapeutic interventions, and improved quality of life in patients and their families.
참고문헌 (57)
- Benchimol EI, "Trends in epidemiology of pediatric inflammatory bowel disease in Canada : distributed network analysis of multiple population-based provincial health administrative databases", Am J Gastroenterol, 112, pp.1120~1134 (2017)
- Benchimol EI, "Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease", Gastroenterology, 147, pp.803~813 (2014)
- El Mouzan MI, "Incidence of pediatric inflammatory bowel disease in Saudi Arabia : a multicenter national study", Inflamm Bowel Dis, 20, pp.1085~1090 (2014)
- Ishige T, "Temporal trend of pediatric inflammatory bowel disease : analysis of national registry data 2004 to 2013 in Japan", J Pediatr Gastroenterol Nutr, 65, pp.e80~2 (2017)
- Benchimol EI, "Epidemiology of pediatric inflammatory bowel disease : a systematic review of international trends", Inflamm Bowel Dis, 17, pp.423~439 (2011)
- Chouraki V, "The changing pattern of Crohn's disease incidence in northern France : a continuing increase in the 10-to 19-year-old age bracket(1988-2007)", Aliment Pharmacol Ther, 33, pp.1133~1142 (2011)
- Ong C, "Rapid rise in the incidence and clinical characteristics of pediatric inflammatory bowel disease in a South-East Asian cohort in Singapore, 1994-2015", J Dig Dis, 19, pp.395~403 (2018)
- Ng SC, "Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century : a systematic review of population-based studies", Lancet, 390, pp.2769~2778 (2018)
- Silverberg MS, "Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology", Can J Gastroenterol, 19(Suppl A), pp.5A~36A (2005)
- Levine A, "Pediatric modification of the Montreal classification for inflammatory bowel disease : the Paris classification", Inflamm Bowel Dis, 17, pp.1314~1321 (2011)
- Uhlig HH, "The diagnostic approach to monogenic very early onset inflammatory bowel disease", Gastroenterology, 147, pp.990~1007 (2014)
- Turpin W, "Determinants of IBD heritability : genes, bugs, and more", Inflamm Bowel Dis, 24, pp.1133~1148 (2018)
- Uhlig HH, "Translating immunology into therapeutic concepts for inflammatory bowel disease", Annu Rev Immunol, 36, pp.755~781 (2018)
- Glocker EO, "Inflammatory bowel disease and mutations affecting the interleukin-10 receptor", N Engl J Med, 361, pp.2033~2045 (2009)
- Jung Ok Shim, "Recent Advance in Very Early Onset Inflammatory Bowel Disease", Pediatric Gastroenterology, Hepatology & Nutrition, 22(1), pp.41~49 (2019), 대한소아소화기영양학회[DOI]
- Ouahed J, "Very early onset inflammatory bowel disease : a clinical approach with a focus on the role of genetics and underlying immune deficiencies", Inflamm Bowel Dis, 26, pp.820~842 (2020)
- Benchimol EI, "Changing age demographics of inflammatory bowel disease in Ontario, Canada : a population-based cohort study of epidemiology trends", Inflamm Bowel Dis, 20, pp.1761~1769 (2014)
- Loftus EV Jr, "Clinical epidemiology of inflammatory bowel disease : incidence, prevalence, and environmental influences", Gastroenterology, 126, pp.1504~1517 (2004)
- Heyman MB, "Children with early-onset inflammatory bowel disease(IBD) : analysis of a pediatric IBD consortium registry", J Pediatr, 146, pp.35~40 (2005)
- "J Crohn's Colitis", 2017, 519~526
- Takeuchi I, "Infliximab for very early-onset inflammatory bowel disease : a tertiary center experience in Japan", J Gastroenterol Hepatol, 35, pp.593~600 (2020)
- Zhou Q, "Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease", Nat Genet, 48, pp.67~73 (2016)
- Kadowaki T, "Haploinsufficiency of A20 causes autoinflammatory and autoimmune disorders", J Allergy Clin Immunol, 14, pp.1485~1488 (2018)
- Umeno J, "A hereditary enteropathy caused by mutations in the SLCO2A1 gene, encoding a prostaglandin transporter", PLoS Genet, 11, pp.e1005581~ (2015)
- Kelsen JR, "North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the evaluation and management for patients with very early-onset inflammatory bowel disease", J Pediatr Gastroenterol Nutr, 70, pp.389~403 (2020)
- Levine A, "ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents", J Pediatr Gastroenterol Nutr, 58, pp.795~806 (2014)
- Watson TA, "European Society of Paediatric Radiology abdominal imaging task force : statement on imaging in very early onset inflammatory bowel disease", Pediatr Radiol, 49, pp.841~848 (2019)
- Nambu R, "Current role of colonoscopy in infants and young children : a multicenter study", BMC Gastroenterol, 19, pp.149~ (2019)
- Obayashi N, "Leopard skin-like colonic mucosa : a novel endoscopic finding of chronic granulomatous disease-associated colitis", J Pediatr Gastroenterol Nutr, 62, pp.56~59 (2016)
- Conrad MA, "Distinct histopathological features at diagnosis of very early onset inflammatory bowel disease", J Crohn's Colitis, 13, pp.615~625 (2019)
- Iwama I, "Efficacy and safety of a capsule endoscope delivery device in children", Eur J Gastroenterol Hepatol, 31, pp.1502~1507 (2019)
- Oikawa-Kawamoto M, "Safety and utility of capsule endoscopy for infants and young children", World J Gastroenterol, 19, pp.8342~8348 (2013)
- Yokoyama K, "Double-balloon enteroscopy for pediatric patients : evaluation of safety and efficacy in 257 cases", J Pediatr Gastroenterol Nutr, 63, pp.34~40 (2016)
- Hagiwara SI, "Clinical safety and utility of pediatric balloon-assisted enteroscopy : a multicenter prospective study in Japan", J Pediatr Gastroenterol Nutr, 68, pp.306~310 (2019)
- Ruemmele FM, "Consensus guidelines of ECCO", ESPGHAN on the medical management of pediatric Crohn's disease, 2014, pp.8, 1179~1207
- Turner D, "Management of paediatric ulcerative colitis, part 1 : ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition", J Pediatr Gastroenterol Nutr, 67, pp.257~291 (2018)
- Turner D, "Management of paediatric ulcerative colitis, part 2 : acute severe colitis-an evidence-based consensus guideline from the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition", J Pediatr Gastroenterol Nutr, 67, pp.292~310 (2018)
- Hyams JS, "Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease", Gastroenterology, 152, pp.1901~1914 (2017)
- Grossman AB, "Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger", Inflamm Bowel Dis, 14, pp.750~755 (2008)
- Kakuta Y, "NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease : a multicenter study", J Gastroenterol, 53, pp.1065~1078 (2018)
- Kakuta Y, "Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia : prospects for clinical application of NUDT15 genotyping", J Gastroenterol, 53, pp.172~180 (2018)
- Kelsen JR, "Infliximab therapy in pediatric patients 7 years of age and younger", J Pediatr Gastroenterol Nutr, 59, pp.758~762 (2014)
- Bramuzzo M, "Efficacy and safety of infliximab in very early onset inflammatory bowel disease : a national comparative retrospective study", United European Gastroenterol J, 7, pp.759~766 (2019)
- Ono S, "Hematopoietic stem cell transplantation for XIAP deficiency in Japan", J Clin Immunol, 37, pp.85~91 (2017)
- Marsh RA, "Allogeneic hematopoietic cell transplantation for XIAP deficiency : an international survey reveals poor outcomes", Blood, 121, pp.877~883 (2013)
- Lum SH, "Conditioning regimens for hematopoietic cell transplantation in primary immunodeficiency", Curr Allergy Asthma Rep, 19, pp.52~ (2019)
- Uzel G, "Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitis", Clin Infect Dis, 51, pp.1429~1434 (2010)
- Kawai T, "Thalidomide attenuates excessive inflammation without interrupting lipopolysaccharide-driven inflammatory cytokine production in chronic granulomatous disease", Clin Immunol, 147, pp.122~128 (2013)
- Sokol H, "Thalidomide as a treatment for refractory CGD colitis", Am J Gastroenterol, 104, pp.1069~ (2009)
- de Luca A, "IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans", Proc Natl Acad Sci U S A, 111, pp.3526~3531 (2014)
- Shouval DS, "Interleukin 1β mediates intestinal inflammation in mice and patients with interleukin 10 receptor deficiency", Gastroenterology, 151, pp.1100~1104 (2016)
- Galeotti C, "Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency", Rheumatology(Oxford), 51, pp.1855~1859 (2012)
- Lo B, "Autoimmune disease. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy", Science, 349, pp.436~440 (2015)
- Dipasquale V, "Vaccination strategies in pediatric inflammatory bowel disease", Vaccine, 35, pp.6070~6075 (2017)
- Kamei K, "Prospective study of live attenuated vaccines for patients with nephrotic syndrome receiving immunosuppressive agents", J Pediatr, 196, pp.217~222 (2018)
- Maxwell EC, "Diverting ileostomy for the treatment of severe, refractory, pediatric inflammatory bowel disease", J Pediatr Gastroenterol Nutr, 65, pp.299~305 (2017)
- Kammermeier J, "Phenotypic and genotypic characterisation of inflammatory bowel disease presenting before the age of 2 years", J Crohn's Colitis, 11, pp.60~69 (2017)